Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04221464
Recruiting Not applicable

Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)

NCT04221464 · tracked via the Priya Life Science France tracker
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Not applicable
Started
2019-11-25
Last updated
2025-02-12

Condition(s) studied

CancerPeritoneal Carcinosis

Investigational drug(s) / intervention(s)

biological collection →Tissues collections

biological collection: Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression

Tissues collections: Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression

Study summary

The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient over the age of 18; * Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer * Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease * Patient agree will all study procedure : biological samples \& tissues samples * Patient giving informed consent Exclusion Criteria: * Patient not affiliated to Social Protection system * Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * The level of French is insufficient to consent to the study and to response to the questionnaires * Patient under guardianship * Pregnancy ou breast-feeding women * Patient treated in case of an emergency

Primary outcome measure(s)

  • Proportion of patients who gave their consent to participate in the study — Until the study completion: 4 years
    The proportion of patients who consent to participate in the study among the screened patients

Trial sites (1)

FacilityCityRegionStatus
Institut du cancer de Montpellier ICM Montpellier France Recruiting

More Institut du Cancer de Montpellier - Val d'Aurelle trials in France

Creation of a Clinical Database on Primary Nervous System Tumors Recruiting
Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability Recruiting
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Recruiting
Study of Sexual Quality of Life in Women With Breast Cancer Who Had Multidisciplinary Management With Photobiomodulation for Genitourinary Syndrome of the Menopause Recruiting
Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique) Recruiting

Other trials for the same condition

Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases Recruiting
ADN Fœtal Circulant, Grossesse et Pathologies Malignes Enrolling by invitation
Evaluation of the Effectiveness of Music Therapy on Anxiety Levels in Patients With Advanced Cancer Hospitalized in a Palliative Care Unit Starting soon
Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine Recruiting
Physical Exercise During the Cancer Care Pathway Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04221464 on ClinicalTrials.gov ↗ ← All trials in France